| Literature DB >> 32384813 |
Shokoh Parham1, Anousheh Zargar Kharazi1, Hamid Reza Bakhsheshi-Rad2, Hamid Ghayour2, Ahmad Fauzi Ismail3, Hadi Nur4,5, Filippo Berto6.
Abstract
Pharmaceutical nano-fibers have attracted widespread attention from researchers for reasons such as adaptability of the electro-spinning process and ease of production. As a flexible method for fabricating nano-fibers, electro-spinning is extensively used. An electro-spinning unit is composed of a pump or syringe, a high voltage current supplier, a metal plate collector and a spinneret. Optimization of the attained nano-fibers is undertaken through manipulation of the variables of the process and formulation, including concentration, viscosity, molecular mass, and physical phenomenon, as well as the environmental parameters including temperature and humidity. The nano-fibers achieved by electro-spinning can be utilized for drug loading. The mixing of two or more medicines can be performed via electro-spinning. Facilitation or inhibition of the burst release of a drug can be achieved by the use of the electro-spinning approach. This potential is anticipated to facilitate progression in applications of drug release modification and tissue engineering (TE). The present review aims to focus on electro-spinning, optimization parameters, pharmacological applications, biological characteristics, and in vivo analyses of the electro-spun nano-fibers. Furthermore, current developments and upcoming investigation directions are outlined for the advancement of electro-spun nano-fibers for TE. Moreover, the possible applications, complications and future developments of these nano-fibers are summarized in detail.Entities:
Keywords: drug delivery; electrospinning; fabrication; nano-fibers; parameters effect; wound dressing
Year: 2020 PMID: 32384813 PMCID: PMC7254207 DOI: 10.3390/ma13092153
Source DB: PubMed Journal: Materials (Basel) ISSN: 1996-1944 Impact factor: 3.623
Figure 1The electro-spun nano-fiber application in different biomedical fields (adapted from Miguel et al. [21]).
Figure 2Electro-spinning methodologies (A) Blend electro-spinning, (B) Coaxial electro-spinning, (C) Emulsion electro-spinning, (D) Needleless electro-spinning (adapted from Repanas et al. [75], Heydari et al. [92], Manuel et al. [104], and Ambekar et al. [126]).
Parameters of electro-spinning of different polymers.
| Polymer | Solvent | Voltage | Tip Collector Distance | Fiber Diameter | Ref. |
|---|---|---|---|---|---|
| PCL (Polycaprolactone) | Formic acid/acetic acid | 12 kV | 12.5 cm | 266 nm | [ |
| PVA (Polyvinyl alcohol) | Deionized water | 22 kV | 10 cm | 240 nm | [ |
| PLA (Poly(lactic acid)) | Acetone | 20 kV | 15 cm | 757 nm | [ |
| PLLA (poly (l-lactic acid) | Chloroform and acetone | 20 kV | 12 cm | 150 nm | [ |
| Chitosan | Acetic acid | 40 kV | -- | 130 nm | [ |
| Silk fibroin | CaCl2/H2O/C2H5OH | 12.5 kV | 21 cm | 700 nm | [ |
| Collagen | Acetic acid | 15–20 kV | 19–21 cm | 100–600 nm | [ |
| Hyaluronic acid (HA) | Deionized water | 22 kV | 15 cm | 200 nm | [ |
| Poly hydroxyl butyrate | Chloroform: Dichloroethane | 20 kV | 7.5 cm | 280 nm | [ |
| Cellulose Acetate | Acetone | 12 kV | 10 cm | 801 nm | [ |
| Poly (glycerol sebacate) | Chloroform/ | 9 kV | 30 cm | 590 nm | [ |
| Elastin | Hexafluoro-2-propanol | 10 kV | 12 cm | 605 nm | [ |
| Gelatin | 2,2,2-trifluoroethanol (TFE) | 10 kV | 13 cm | 200–300 nm | [ |
| Poly (ethylene-co-vinyl alcohol) | Deionized water/isopropyl alcohol (IPA) | 15 kV | 15 cm | 500 nm | [ |
| Chitin | 1,1,1,2,2,2-hexafluoro-2-propanol (HFIP) | 15 kV | 7 cm | 100 nm | [ |
Effects of electro-spinning equipment setup and their corresponding parameters on the characteristics of polymer-based electro-spinning.
| Polymer | Electrospinning Technique | Fiber Diameter | Application | Condition | Results | Ref. |
|---|---|---|---|---|---|---|
| Collagen + Silk fibroin (SF) | Blend | 320–360 nm | Wound healing | In vitro | The cell attachment is 300 cells/0.53 mm2 | [ |
| PCL | Blend | 250 nm | Wound healing | In vitro | The duration of the cell culture proliferation is around 7 days | [ |
| Poly (L-lactide) + Poly (D-lactide) | Blend | 300 nm | Wound healing | In vitro and In vivo | Crystallinity 61% -4 week (Before implantation) and 49% (after implantation) | [ |
| Chitosan + PCL | Blend | 177 nm | Acute and chronic wound healing | In vitro and In vivo | 45% wound recovery in during 6 days | [ |
| PCL + BC (Bacterial cellulose) | Blend | 400 nm | Wound dressing - | In vitro | The 100% cell viability has been appeared in during 72 h | [ |
| Carboxyethyl chitosan (CECS) + PVA | Blend | 131–456 nm | Wound dressing | In vitro | The adhesion study of the L929 cells (48 h) | [ |
| Chitosan/poly ethylene oxide | Blend | 60-120 nm | Wound dressing | In vitro | The viscosity is 2.25 Pa.s and electric conductivity is 3 mS/cm | [ |
| PEG-Lysozyme PEG-Bovine Serum Albumin (BSA) + PCL | Co-axial | 571 nm | Wound healing | In vitro | 50% drug release in during 24 day | [ |
| PLA + collagen | Co-axial | 168 nm | Wound dressing | In vitro | The cell viability has been increased during 14 days and antimicrobial efficiency against | [ |
| PLA + Chitosan (CS) | Co-axial | 236 nm | Wound healing | In vitro | The antibacterial efficiency against E. coli bacteria | [ |
| Chitosan + PEG | Blend | 50–200 nm | Wound healing | In vivo | The time of the cells spreading is around 3 days | [ |
| Poly-(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV)/Ag nanofibers poly | Emulsion | 603 nm | Wound healing | In vitro | The drug release of the AgNPs is 0.55 ppm during 30 days | [ |
| (Llactide-co-D, L-lactide) + poly (vinyl alcohol) | Blend | 275 nm | Wound dressing | In vitro | The anti-bacterial efficiency against | [ |
| Dimethyloxalylglycine (DMOG) PCL/Col I | Co-axial | 200–500 nm | Wound healing | In vivo | 53% drug release of nanofiber during 12 h and 72% during 24 h. drug release of core/shell nanofibers: 17% during 12 h and 36% during 24 h | [ |
| Polyhydroxybutyrate (PHB) + Gelatin (GEL) | Blend | 80 nm | Wound healing | In vitro and in vivo | The 71.8% degradation rate during 12 h | [ |
| Gelatin/Oleoyl Chitosan (OC) | Blend | 150–400 nm | Full-Thickness Excisional Wound Healing | In vitro | The swelling is around 380% and the water contact angle is 80° | [ |
| Chitosan + PEO | Co-axial | 250 nm | Wound healing | In vitro | The tensile strength is 4.0 MPa and porosity is around 84% | [ |
| Gelatin + poly-methyl vinyl ether-altmaleic anhydride (PMVE/MA) + nano zinc oxide | Emulsion | 500–700 nm | Wound healing | In vivo | 99% wound healing during 10 days | [ |
| Dimethyloxalylglycine (DMOG) + PLLA | Co-axial | --- | Diabetic wound, chronic wound | In vivo | 97% wound healing happened during 15 days | [ |
| Polyurethanes without dendrimer + Polyurethanes with NO-releasing dendrimer | Co-axial | 393 nm | Wound dressing | In vitro | The NO release during 9 h | [ |
Summary of the drug delivery of different drugs and their biomedical applications.
| Drug | Polymer | Electrospinning Method | Application | Ref. |
|---|---|---|---|---|
| Ascorbylpalmitate | PCL | Blend | Infection treatment | [ |
| Amoxicillin | PCL; PLGA | Blend | Infection treatment | [ |
| Ampicillin | PMMA/nylon; PCL | Blend; Co-axial | Infection treatment | [ |
| Berberine | Collagen/ZN | Blend | Infection treatment | [ |
| Cilostazol | PCL | Blend | Preventing coagulation of blood | [ |
| Cefazolin | Gel; PLGA | Blend | Infection treatment | [ |
| Cefoxitin | PLGA/PEG-b-PLA | Blend | Infection treatment | [ |
| Ciprofloxacin | PCNU; PGS/PHB | Blend; Co-axial | Infection treatment | [ |
| Captopril | PLLA/PLCL/PLGA | Blend | Preventing the complications of high blood pressure | [ |
| Doxorubicin | PEG/PLA | Emulsion | Cancer therapy | [ |
| Doxycycline | Span 60; PCL; SLS | Emulsion | Infection treatment | [ |
| Fusidic acid | PLGA | Blend | Infection treatment | [ |
| Gentamycin | CS, PCL | Blend; Co-axial | Infection treatment | [ |
| Indomethacin | ERS/ES | Blend | Reducing inflammation | [ |
| Ketoprofen | PVP | Blend | Reducing inflammation | [ |
| Lidocaine | PLLA | Co-axial | Ventricular treatment tachycardia and nerve blocker | [ |
| Mefoxin | PDLA/PLLA; PLGA | Blend | Infection treatment | [ |
| Metronidazole | PCL | Blend | Infection treatment in periodontal diseases | [ |
| Mupirocin | PCL | Blend | Infection treatment | [ |
| Nifedipine | PLGA | Blend | Prevent the complications of high blood pressure | [ |
| Paclitaxel | PLGA | Blend | Cancer therapy | [ |
| Rifampicin | PLLA | Blend | Infection treatment | [ |
| Resveratrol | PCL | Blend | Inflammation treatment | [ |
| Simvastatin | PGS/PHB | Co-axial | Infection treatment | [ |
| Salicylic Acid | CS/ZN | Blend | Infection treatment and reducing inflammation | [ |
| Streptomycin | PU/CA/Zein | Blend | Infection treatment | [ |
| Tetracycline | PCl/CA/Dextran; PLA/PEVA; PVA/CS | Blend | Infection treatment | [ |
| Tenofovir | PVA; CAP | Blend; Needleless | Treatment of viral infections | [ |
CAP: cellulose acetate phthalate; PHB: poly (hydroxybutyrate; PLLA: Poly (l-lactic acid); PEVA: poly (ethylene-co-vinyl acetate; CA: Cellulose acetate; CS: Chitosan; PLCL: poly (lactic-co-Ԑ-caprolactone; ERS:Eudragit RS100; ES: Eudragit S100; Gel: Gelatin; PCL: Polycaprolactone; PDLA: Poly-d-lactide; PEG: Poly (ethylene glycol); PLA: Poly (lactic acid); SLS: sodium lauryl salt; PEUU: Poly (ester urethane) urea; PCNU: Polycarbonate urethane; PLGA: Poly Lactic-co-Glycolic Acid; PGS: Poly (glycerol sebacate); PLLCL: Poly (llactic acid)-b-poly (-caprolactone); PMMA: Poly (methyl methacrylate); PU: Polyurethane; PVA: Polyvinyl alcohol; PVP: Polyvinylpyrrolidone; ZN: Zein.
Figure 3The in vivo wound healing process ((a) Hemostasis stage (b) Inflammation stage (c) Proliferation stage (d) Remodeling stage) by electro-spinning wound dressing (adapted from Farokhi et al. [199]).